CN101142322A - 用于预测华法令敏感性的基因变体 - Google Patents
用于预测华法令敏感性的基因变体 Download PDFInfo
- Publication number
- CN101142322A CN101142322A CNA2005800485213A CN200580048521A CN101142322A CN 101142322 A CN101142322 A CN 101142322A CN A2005800485213 A CNA2005800485213 A CN A2005800485213A CN 200580048521 A CN200580048521 A CN 200580048521A CN 101142322 A CN101142322 A CN 101142322A
- Authority
- CN
- China
- Prior art keywords
- warfarin
- sequence
- oligonucleotide
- nucleotide
- vkorc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Abstract
Description
病例号 | 剂量(mg/d) | INR | 年龄(yr) | 性别 | 体重(kg) | VKORC1-1639 | VKORC11173 | #CYP2C9变体 | ||||
华法令敏感组(剂量≤1.5mg/天,n=11) | ||||||||||||
1234567891011 | 0.71111.251.251.251.251.251.251.431.5 | 3.232.693.231.51.962.522.91.592.052.24 | 6574708468717172675861 | FMMFMFFFMFM | 4265665075708067584265 | AAAAAAAAAAAAAAAAAAAAAA | TTTTTTTTTTCTTTTTTTTTTT | CYP2C9*3正常CYP2C9*3正常CYP2C9*3895A>G(T299A)1145C>T(P382L)正常正常正常正常正常 | ||||
华法令抗性组(剂量≥6mg/天, n=5) | ||||||||||||
1213141516 | 6.078.578.751010 | 2.822.092.321.32.33 | 4863264658 | FFMMF | 5258886461 | AGGGGGAGGG | CTCCCCCTCC | 正常正常正常正常正常 |
基因型 | 华法令剂量(mg/天) | INR | 年龄(年) | 性别(M/F) |
VKORC1-1639 | ||||
AA(n=83)AG+GG(n=21) | 2.61±1.10a3.81±1.24 | 2.03±0.452.08±0.47 | 57.5±14.860.4±13.1 | 43/4013/8 |
基因型 | 高加索人(n=92) | 华人(n=95) | 随机选出的服用华法令的华人患者(n=104) |
VKORC1-1639 | |||
AAAGGG | 13(14.2%)43(46.7%)36(39.1%) | 78(82.1%)17(17.9%)0(0%) | 83(79.8%)19(18.3%)2(1.9%) |
CYP2C9变体a | |||
2C9*1*22C9*2*22C9*1*32C9*3*3 | 20.4%0.9%11.6%0.4% | 0(0%)0(0%)7(7.3%)0(0%) | 0(0%)b0(0%)b4(5.4%)b0(0%)b |
VKORC1-1639 | CYP2C9变体 | 推荐的剂量 |
GG | *1 | 5 |
*2 | 3.75 | |
*3 | 3.75 | |
AG | *1 | 3.75 |
*2 | 2.5 | |
*3 | 2.5 | |
AA | *1 | 2.5 |
*2 | 1.25 | |
*3 | 1.25 |
Claims (25)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63883704P | 2004-12-21 | 2004-12-21 | |
US60/638,837 | 2004-12-21 | ||
US67969405P | 2005-05-10 | 2005-05-10 | |
US60/679,694 | 2005-05-10 | ||
PCT/US2005/046869 WO2006069339A2 (en) | 2004-12-21 | 2005-12-21 | Genetic variants of vkorci predicting warfarin sensitivity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101142322A true CN101142322A (zh) | 2008-03-12 |
CN101142322B CN101142322B (zh) | 2011-09-21 |
Family
ID=36602356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800485213A Active CN101142322B (zh) | 2004-12-21 | 2005-12-21 | 用于预测华法令敏感性的基因变体 |
Country Status (19)
Country | Link |
---|---|
US (2) | US20060166239A1 (zh) |
EP (2) | EP1831402B1 (zh) |
JP (1) | JP4516990B2 (zh) |
KR (1) | KR101178463B1 (zh) |
CN (1) | CN101142322B (zh) |
AT (1) | ATE470725T1 (zh) |
AU (1) | AU2005319028B2 (zh) |
BR (1) | BRPI0519570A2 (zh) |
CA (1) | CA2591840C (zh) |
DE (1) | DE602005021821D1 (zh) |
DK (1) | DK1831402T3 (zh) |
ES (1) | ES2347167T3 (zh) |
HK (1) | HK1117571A1 (zh) |
MX (1) | MX2007007568A (zh) |
NZ (1) | NZ556461A (zh) |
PL (1) | PL1831402T3 (zh) |
PT (1) | PT1831402E (zh) |
TW (1) | TWI334886B (zh) |
WO (1) | WO2006069339A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103173443A (zh) * | 2013-03-22 | 2013-06-26 | 卫生部北京医院 | 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用 |
CN110592206A (zh) * | 2019-09-11 | 2019-12-20 | 上海交通大学 | 一种利用rs9934438检测华法药效的试剂盒 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2575903T3 (es) | 2003-02-20 | 2016-07-04 | Mayo Foundation For Medical Education And Research | Métodos para seleccionar medicamentos antidepresivos |
US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
ES2339710T5 (es) * | 2003-09-23 | 2017-10-05 | University Of North Carolina At Chapel Hill | Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K |
US7445896B2 (en) * | 2004-10-18 | 2008-11-04 | University Of Washington | Methods and compositions for detecting VKORC1 single nucleotide polymorphisms |
US20090325226A1 (en) | 2005-03-15 | 2009-12-31 | Stafford Darrel W | Methods and Compositions for Producing Active Vitamin K-Dependent Proteins |
CA2911569C (en) * | 2005-11-29 | 2019-11-26 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
US8380539B2 (en) * | 2006-05-09 | 2013-02-19 | University Of Louisville Research Foundation, Inc. | Personalized medicine management software |
US8039212B2 (en) * | 2007-11-05 | 2011-10-18 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
ES2927105T3 (es) * | 2008-10-20 | 2022-11-02 | Epitome Pharmaceuticals Ltd | Métodos y sistemas para mejorar la intervención farmacéutica en el control de la coagulación |
KR101157135B1 (ko) * | 2008-12-29 | 2012-06-18 | 인제대학교 산학협력단 | 항응고제의 약물반응과 관련된 유전자의 변이 유전형 결정방법 |
EP2233580A1 (en) * | 2009-03-05 | 2010-09-29 | The Ohio State University | Rapid genotyping of SNPs |
JP5843487B2 (ja) * | 2010-06-01 | 2016-01-13 | アークレイ株式会社 | Vkorc1遺伝子の−1639番目の塩基の多型検出法、ならびにそのための核酸プローブおよびキット |
US9631002B2 (en) | 2010-12-21 | 2017-04-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin K-dependent proteins |
EP2708895B1 (en) * | 2012-08-21 | 2019-05-08 | Industrial Technology Research Institute | Method for identifying more than one target nucleic acid contained in a sample |
EP4119663A1 (en) | 2016-12-09 | 2023-01-18 | The Broad Institute, Inc. | Crispr effector system based diagnostics |
US11174515B2 (en) | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
CN111742370A (zh) * | 2017-05-12 | 2020-10-02 | 密歇根大学董事会 | 个体和队列药理学表型预测平台 |
AU2019213047A1 (en) | 2018-01-29 | 2020-07-16 | Massachusetts Institute Of Technology | CRISPR effector system based diagnostics |
WO2020186223A1 (en) | 2019-03-14 | 2020-09-17 | The Broad Institute, Inc. | Sherlock assays for tick-borne diseases |
KR102506347B1 (ko) | 2021-05-11 | 2023-03-03 | 충북대학교 산학협력단 | 와파린 치료에 따른 출혈 부작용 위험 예측용 다형성 마커 및 이를 이용한 와파린 치료에 따른 출혈 부작용 위험 예측 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492115B1 (en) * | 2000-06-02 | 2002-12-10 | Dna Sciences Laboratories, Inc. | Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods |
ES2339710T5 (es) * | 2003-09-23 | 2017-10-05 | University Of North Carolina At Chapel Hill | Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K |
EP1809767B1 (en) * | 2004-10-18 | 2011-09-07 | University of Washington | Methods and compositions for predicting response to warfarin |
US7445896B2 (en) * | 2004-10-18 | 2008-11-04 | University Of Washington | Methods and compositions for detecting VKORC1 single nucleotide polymorphisms |
US20080005732A1 (en) * | 2006-05-11 | 2008-01-03 | Coon Robert F | Method and System for Integrating Software Update Services with Software Applications |
-
2005
- 2005-12-21 NZ NZ556461A patent/NZ556461A/en unknown
- 2005-12-21 AT AT05855433T patent/ATE470725T1/de active
- 2005-12-21 TW TW094145510A patent/TWI334886B/zh active
- 2005-12-21 DK DK05855433.8T patent/DK1831402T3/da active
- 2005-12-21 DE DE602005021821T patent/DE602005021821D1/de active Active
- 2005-12-21 PT PT05855433T patent/PT1831402E/pt unknown
- 2005-12-21 MX MX2007007568A patent/MX2007007568A/es active IP Right Grant
- 2005-12-21 ES ES05855433T patent/ES2347167T3/es active Active
- 2005-12-21 CN CN2005800485213A patent/CN101142322B/zh active Active
- 2005-12-21 WO PCT/US2005/046869 patent/WO2006069339A2/en active Application Filing
- 2005-12-21 BR BRPI0519570-5A patent/BRPI0519570A2/pt active Search and Examination
- 2005-12-21 EP EP05855433A patent/EP1831402B1/en active Active
- 2005-12-21 EP EP10165009A patent/EP2246445A1/en not_active Withdrawn
- 2005-12-21 AU AU2005319028A patent/AU2005319028B2/en active Active
- 2005-12-21 US US11/316,406 patent/US20060166239A1/en not_active Abandoned
- 2005-12-21 KR KR1020077016947A patent/KR101178463B1/ko active IP Right Grant
- 2005-12-21 JP JP2007548549A patent/JP4516990B2/ja active Active
- 2005-12-21 CA CA2591840A patent/CA2591840C/en active Active
- 2005-12-21 PL PL05855433T patent/PL1831402T3/pl unknown
-
2008
- 2008-08-07 HK HK08108714.0A patent/HK1117571A1/xx unknown
-
2010
- 2010-03-12 US US12/722,672 patent/US20110236885A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103173443A (zh) * | 2013-03-22 | 2013-06-26 | 卫生部北京医院 | 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用 |
CN103173443B (zh) * | 2013-03-22 | 2016-08-24 | 卫生部北京医院 | 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用 |
CN110592206A (zh) * | 2019-09-11 | 2019-12-20 | 上海交通大学 | 一种利用rs9934438检测华法药效的试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
JP4516990B2 (ja) | 2010-08-04 |
WO2006069339A2 (en) | 2006-06-29 |
PT1831402E (pt) | 2010-09-10 |
AU2005319028B2 (en) | 2010-09-16 |
PL1831402T3 (pl) | 2010-12-31 |
HK1117571A1 (en) | 2009-01-16 |
WO2006069339A3 (en) | 2006-10-12 |
US20060166239A1 (en) | 2006-07-27 |
TWI334886B (en) | 2010-12-21 |
KR20080005179A (ko) | 2008-01-10 |
EP1831402B1 (en) | 2010-06-09 |
DE602005021821D1 (de) | 2010-07-22 |
ATE470725T1 (de) | 2010-06-15 |
MX2007007568A (es) | 2008-03-11 |
CN101142322B (zh) | 2011-09-21 |
NZ556461A (en) | 2009-12-24 |
EP1831402A2 (en) | 2007-09-12 |
WO2006069339A8 (en) | 2010-06-03 |
CA2591840C (en) | 2012-07-10 |
ES2347167T3 (es) | 2010-10-26 |
JP2008523844A (ja) | 2008-07-10 |
DK1831402T3 (da) | 2010-09-20 |
US20110236885A1 (en) | 2011-09-29 |
AU2005319028A1 (en) | 2006-06-29 |
EP2246445A1 (en) | 2010-11-03 |
CA2591840A1 (en) | 2006-06-29 |
BRPI0519570A2 (pt) | 2009-01-27 |
TW200637918A (en) | 2006-11-01 |
KR101178463B1 (ko) | 2012-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101142322B (zh) | 用于预测华法令敏感性的基因变体 | |
Yuan et al. | A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity | |
US20070298426A1 (en) | Warfarin dosage prediction | |
US7300754B2 (en) | Methods for detecting the presence of or predisposition to autosomal dominant hypercholesterolemia | |
JP2008523844A5 (ja) | ワルファリンの投与範囲を予想する方法 | |
Gao et al. | A polymorphism of matrix Gla protein gene is associated with kidney stones | |
Hillarp et al. | Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke | |
US20110189675A1 (en) | Method For Administering Anticoagulation Therapy | |
AU2006301578B9 (en) | Method for diagnosing thromboembolic disorders and coronary heart diseases | |
Rungroj et al. | A whole genome SNP genotyping by DNA microarray and candidate gene association study for kidney stone disease | |
WO2004001037A1 (ja) | 心筋梗塞のリスク診断方法 | |
US20140072966A1 (en) | Genetic biomarkers for glucose-6-phosphate dehydrogenase deficiency | |
US20100267020A1 (en) | Genetic risk factor for neurodegenerative disease | |
Hao et al. | Allele and genotype frequencies of polymorphic FMO3 gene in two genetically distinct populations | |
JP4956565B2 (ja) | Edg5遺伝子多形v286aと二型糖尿病および静脈血栓症/肺塞栓症との関連性、並びに、その利用 | |
JP2010515467A (ja) | 心筋梗塞及び心不全における診断マーカー及び薬剤設計のためのプラットホーム | |
KR101799152B1 (ko) | Pd-l1 다형성을 이용한 비소세포폐암 환자의 예후 진단방법 | |
US8198022B2 (en) | Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof | |
CA2501253A1 (en) | Means and methods for individualized drug therapy and for predicting adverse drug reaction | |
CN103045625A (zh) | 心肌梗死相关基因及其体外检测的试剂、制剂或试剂盒、应用 | |
Jin et al. | Association between prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and blood pressure in Korean population |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1117571 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1117571 Country of ref document: HK |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20080312 Assignee: Pharmigene, Inc. Assignor: Academia Sinica Contract record no.: 2014990000748 Denomination of invention: Genetic variants predicting warfarin sensitivity Granted publication date: 20110921 License type: Exclusive License Record date: 20140916 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model |